- Eledon Pharmaceuticals ( NASDAQ: ELDN ) said the first patient was dosed in a phase 1b trial of tegoprubart in patients undergoing kidney transplantation.
- In the study, which received clearance in Canada and the U. K., is enrolling up to 12 patients who will undergo kidney transplantation and will receive tegoprubart in combination with rabbit anti-thymocyte globulin (rATG) induction, and mycophenolate mofetil and an oral steroid taper as maintenance therapy.
- "We believe tegoprubart has the potential to transform the clinical management of kidney transplantation by preventing graft rejection, mitigating the multiple toxicities associated with CNIs, and ultimately improving long term outcomes," said Eledon CEO David-Alexandre Gros.
- In June, the U.S. Food and Drug Administration granted orphan drug designation to tegoprubart for preventing allograft rejection in pancreatic islet cell transplantation.
For further details see:
Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients